Athens sees biotech as a route to investment and pharma production, while Warsaw pushes for simpler rules, prevention and a broader mental-health agenda
Greece and Poland are looking to Ireland’s EU Council presidency to advance legislation they see as crucial to Europe’s health resilience and competitiveness, with Athens particularly focused on biotechnology, clinical trials and pharmaceutical production, and Warsaw highlighting medicines security, regulatory simplification and mental health.
With Ireland now nearly two months into its six-month presidency, both countries are closely watching progress on the European Biotech Act, the Critical Medicines Act and revisions to medical-device rules. For Greece, the road ahead is critical, as it prepares for its own Council presidency in the second half of 2027 and aims to implement domestic reforms.
Ireland has made health and life sciences a key part of its broader competitiveness agenda, with the Biotech Act and simplified medical device rules among its main legislative priorities.
Biotech linked to Greek efforts
